741 related articles for article (PubMed ID: 29934056)
1. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
[TBL] [Abstract][Full Text] [Related]
2. Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE).
Wolf J; Kalocsai K; Fortuny C; Lazar S; Bosis S; Korczowski B; Petit A; Bradford D; Croos-Dabrera R; Incera E; Melis J; van Maanen R
Clin Infect Dis; 2020 Dec; 71(10):2581-2588. PubMed ID: 31773143
[TBL] [Abstract][Full Text] [Related]
4. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
[TBL] [Abstract][Full Text] [Related]
5. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
Cornely OA; Crook DW; Esposito R; Poirier A; Somero MS; Weiss K; Sears P; Gorbach S;
Lancet Infect Dis; 2012 Apr; 12(4):281-9. PubMed ID: 22321770
[TBL] [Abstract][Full Text] [Related]
6. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial.
Lee CH; Patino H; Stevens C; Rege S; Chesnel L; Louie T; Mullane KM
J Antimicrob Chemother; 2016 Oct; 71(10):2964-71. PubMed ID: 27432604
[TBL] [Abstract][Full Text] [Related]
7. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
Crawford T; Huesgen E; Danziger L
Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
[TBL] [Abstract][Full Text] [Related]
8. Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital.
Pichenot M; Héquette-Ruz R; Le Guern R; Grandbastien B; Charlet C; Wallet F; Schiettecatte S; Loeuillet F; Guery B; Galperine T
Infection; 2017 Aug; 45(4):425-431. PubMed ID: 28120176
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.
Nelson RL; Suda KJ; Evans CT
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD004610. PubMed ID: 28257555
[TBL] [Abstract][Full Text] [Related]
10. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
[TBL] [Abstract][Full Text] [Related]
11. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
Cornely OA
Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.
Cornely OA; Nathwani D; Ivanescu C; Odufowora-Sita O; Retsa P; Odeyemi IA
J Antimicrob Chemother; 2014 Nov; 69(11):2892-900. PubMed ID: 25074856
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
Watt M; Dinh A; Le Monnier A; Tilleul P
J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
[TBL] [Abstract][Full Text] [Related]
14. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses.
Cornely OA; Vehreschild MJGT; Adomakoh N; Georgopali A; Karas A; Kazeem G; Guery B
Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1187-1194. PubMed ID: 30911926
[TBL] [Abstract][Full Text] [Related]
15. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.
Petrella LA; Sambol SP; Cheknis A; Nagaro K; Kean Y; Sears PS; Babakhani F; Johnson S; Gerding DN
Clin Infect Dis; 2012 Aug; 55(3):351-7. PubMed ID: 22523271
[TBL] [Abstract][Full Text] [Related]
16. [Antimicrobial profile and clinical evidence of fidaxomicin (Dafclir
Takeda S; Miki T
Nihon Yakurigaku Zasshi; 2019; 154(4):217-229. PubMed ID: 31597902
[TBL] [Abstract][Full Text] [Related]
17. Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials.
Gerding DN; Cornely OA; Grill S; Kracker H; Marrast AC; Nord CE; Talbot GH; Buitrago M; Gheorghe Diaconescu I; Murta de Oliveira C; Preotescu L; Pullman J; Louie TJ; Wilcox MH
Lancet Infect Dis; 2019 Mar; 19(3):265-274. PubMed ID: 30709665
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan.
Okumura H; Ueyama M; Shoji S; English M
J Infect Chemother; 2020 Jun; 26(6):611-618. PubMed ID: 32165072
[TBL] [Abstract][Full Text] [Related]
19. Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection.
Hvas CL; Dahl Jørgensen SM; Jørgensen SP; Storgaard M; Lemming L; Hansen MM; Erikstrup C; Dahlerup JF
Gastroenterology; 2019 Apr; 156(5):1324-1332.e3. PubMed ID: 30610862
[TBL] [Abstract][Full Text] [Related]
20. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.
Crook DW; Walker AS; Kean Y; Weiss K; Cornely OA; Miller MA; Esposito R; Louie TJ; Stoesser NE; Young BC; Angus BJ; Gorbach SL; Peto TE;
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S93-103. PubMed ID: 22752871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]